Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. - Wikidata - awgldk - TriplyDB

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.

http://www.wikidata.org/entity/Q37095593

about

New and emerging HDAC inhibitors for cancer treatment Nicotinamide in Friedreich's ataxia: useful or not?A GAA repeat expansion reporter model of Friedreich's ataxia recapitulates the genomic context and allows rapid screening of therapeutic compounds.Epigenetic therapy for Friedreich ataxia TORC1 Inhibition by Rapamycin Promotes Antioxidant Defences in a Drosophila Model of Friedreich's Ataxia Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia.Targeting class I histone deacetylases in cancer therapy.Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.Epigenetic-based therapies for Friedreich ataxia.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Emerging approaches for histone deacetylase inhibitor drug discovery.Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation.Therapeutic approaches for the treatment of Friedreich's ataxia.Translating HDAC inhibitors in Friedreich's ataxia.Pharmacological therapeutics in Friedreich ataxia: the present state.

P2860

Q27022413-B5743047-72BE-4941-A5E4-C978697DFE07 Q34846058-8F1B45A2-7769-4148-B14F-382562F59DF7 Q34940777-CB1D9777-EE1D-4E24-B046-E69754EE3BAF Q35180607-01C09C86-470A-4F09-9921-2F327030ECD5 Q35687064-8435E98A-87D4-4F01-AC1C-36430BC04B5E Q37155503-F22F288A-2D2C-4500-95A9-EF7F36690E69 Q38051736-9ABB14C0-19B0-4CD7-95C8-84C7D82903C5 Q38215303-385A8BB3-5A54-417F-A299-22D919C58977 Q38219414-494F0860-0904-4262-83A3-CA910DA198AC Q38240733-FFC63098-A682-4551-9574-50B2BE7B8015 Q38431356-05320FD5-ABEB-4E33-8C76-F4ADCF28FC57 Q38976490-3671499D-B1D5-48C1-B056-BAFA226F6742 Q39158402-C794C5C1-1DDE-417F-919C-6A0E8F8F93A9 Q39230731-F5E0A5FD-15B6-470B-B66D-4B67587D70D5 Q39445743-3DC570D2-33E3-4F19-8FB2-7DD8EAC5F77B

P2860

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.

http://www.wikidata.org/entity/Q37095593

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 July 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Rationale for the development ...... peutics for Friedreich ataxia.

@en

Rationale for the development ...... peutics for Friedreich ataxia.

@nl

type

label

Rationale for the development ...... peutics for Friedreich ataxia.

@en

Rationale for the development ...... peutics for Friedreich ataxia.

@nl

prefLabel

Rationale for the development ...... peutics for Friedreich ataxia.

@en

Rationale for the development ...... peutics for Friedreich ataxia.

@nl

P1433

Q37095593-71DB684F-8943-4D0A-9444-725F659EBEE3

P1476

Q37095593-55582DF1-D0A4-4249-B341-15E0DE9F3443

P2093

Q37095593-58E2D369-0E8D-418C-B566-9C28C9C7BDFE

Q37095593-9EB27D13-4B52-49D1-BDE7-DBD6D9F42F6B

Q37095593-A4D64A7F-BD73-479B-B3EF-BB6E50DC886A

Q37095593-DCF7C9D7-C651-490C-8B24-A77B3EB82C46

Q37095593-F0BEA475-5B6C-4FDC-A809-9DAFEA75D103

Q37095593-F2977673-86E8-49E9-902F-7A34ECA4B680

P2860

Q37095593-072959A1-AA3C-4023-95C5-1C2B80948F81

Q37095593-09BE41B4-1CDC-4B81-94F6-E943CF0C9518

Q37095593-1441C2E5-52C3-47F6-9E9F-5E4E479335D0

Q37095593-149FED70-E508-4540-B9A6-7A36B080CD8C

Q37095593-19EE0A54-B782-4A8C-8E86-76EC59F00FC3

Q37095593-20FBEB75-1B30-4D67-B28A-DF348CE0B5F6

Q37095593-26B2E730-C3EE-47B4-A4F7-7B7F8D07CF65

Q37095593-2E7DF93B-F529-44DD-A7BE-AE8E0B8CE19E

Q37095593-3822498F-B777-4FD2-8FA0-46964AD0C9B7

Q37095593-387E7E74-2AF8-4EA8-AEA5-D4852BCED1AF

P304

Q37095593-448DCAF8-9124-4138-893C-35103A175155

P31

Q37095593-C353D17B-39A0-4B1C-9D9B-EB26B2B3DA06

P356

Q37095593-9EAC8DC0-847B-4A51-B8B0-C42E5268A99E

P433

Q37095593-AF3798B6-1FCF-465E-BC6F-A9D087C58157

P478

Q37095593-7A407D8F-57F4-4276-A4B2-0BE60DC342E7

P577

Q37095593-74B1D8D0-E5D6-43DC-988D-A0C76C0F72DB

P698

Q37095593-9800E174-39D3-4736-B6AA-5ACCE0B80214

P932

Q37095593-3A30CE71-00FB-4EA2-890C-62404A561AF3

P356

0883073812448533

P1433

Journal of Child Neurology

P1476

Rationale for the development ...... peutics for Friedreich ataxia.

@en

P2093

Chunping Xu

http://www.w3.org/2001/XMLSchema#string

Elisabetta Soragni

http://www.w3.org/2001/XMLSchema#string

Heather L Plasterer

http://www.w3.org/2001/XMLSchema#string

James R Rusche

http://www.w3.org/2001/XMLSchema#string

Joel M Gottesfeld

http://www.w3.org/2001/XMLSchema#string

Vincent Jacques

http://www.w3.org/2001/XMLSchema#string

P2860

The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure

Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia

Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease

Influence of Friedreich ataxia GAA noncoding repeat expansions on pre-mRNA processing

Friedreich ataxia: an overview

HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model

Clinical development of histone deacetylase inhibitors as anticancer agents

Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

Trinucleotide Repeat Disorders

P304

1164-1173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0883073812448533

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22764181

http://www.w3.org/2001/XMLSchema#string

P932

3743553

http://www.w3.org/2001/XMLSchema#string